Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin

Cancer Treatment Reviews

Volumn 40, Issue 3, 2014, Pages 366-375

  Poveda, Andrés ^a   Ray Coquard, Isabelle ^b   Romero, Ignacio ^a   Lopez Guerrero, Jose Antonio ^a   Colombo, Nicoletta ^c  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Platinum sensitive; PLD; Recurrent ovarian cancer; Trabectedin

Indexed keywords

BEVACIZUMAB; CEDIRANIB; DOXORUBICIN; OLAPARIB; PAZOPANIB; PLATINUM; TRABECTEDIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; HUMAN; INTERVENTION STUDY; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

PLATINUM-SENSITIVE; PLD; RECURRENT OVARIAN CANCER; TRABECTEDIN;

ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; TETRAHYDROISOQUINOLINES;

EID: 84892860463     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.08.001     Document Type: Review

References (99)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Cannistra S.A., Bast R.C., Berek J.S., et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003, 21(Suppl. 10):129-132.
3. Harter P., Hilpertm F., Mahner S., Heitz F., Pfisterer J., Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 2010, 10(1):81-88.
4. Colombo N., Van Gorp T., Parma G., et al. Ovarian cancer. Crit Rev Oncol Hematol 2006, 60(2):159-179.
5. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7(Suppl. 5):20-28.
6. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9(6):415-428.
7. Stuart G.C., Kitchener H., Bacon M., et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011, 21(4):750-755.
8. Friedlander M., Trimble E., Tinker A., et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011, 21(4):771-775.
9. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36(2):207-211.
10. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989, 59:650-653.
11. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9(3):389-393.
12. Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol 2012, 23(Suppl. 10):128-131.
13. Hall M., Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 2011, 13(6):459-471.
14. Markman M., Markman J., Webster K., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004, 22(15):3120-3125.
15. Colombo N., Gore M. Treatment of recurrent ovarian cancer relapsing 6-12months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007, 64(2):129-138.
16. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361(9375):2099-2106.
17. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24(29):4699-4707.
18. Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28(20):3323-3329.
19. Monk B.J., Herzog T.J., Kaye S.B., et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28(19):3107-3114.
20. Aghajanian C., Blank S.V., Goff B.A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30(17):2039-2045.
21. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4(2):87-94.
22. See H.T., Freedman R.S., Kudelka A.P., et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005, 15(2):209-216.
23. Kavanagh J., Tresukosol D., Edwards C., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995, 13(7):1584-1588.
24. Monk B.J., Coleman R.L. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009, 19(Suppl. 2):S63-S67.
25. Pignata S., Ferrandina G., Scarfone G., et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 2006, 71(5-6):320-326.
26. Chuang Y.T., Chang C.L. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance. Taiwan J Obstet Gyne 2012, 51(3):336-341.
27. Kaye S.B., Colombo N., Monk B.J., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011, 22(1):49-58.
28. Vaughan S., Coward J.I., Bast R.C., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011, 11(10):719-725.
29. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
30. Yang D., Khan S., Sun Y., et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Jama 2011, 306(14):1557-1565.
31. Majdak E.J., Debniak J., Milczek T., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005, 104(5):1004-1012.
32. Bolton K.L., Chenevix-Trench G., Goh C., et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Jama 2012, 307(4):382-390.
33. Varga D., Deniz M., Schwentner L., Wiesmuller L. Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci 2013, 14(1):640-673.
34. Weberpals J., Garbuio K., O'Brien A., et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009, 124(4):806-815.
35. Carser J.E., Quinn J.E., Michie C.O., et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 2011, 123(3):492-498.
36. Quinn J.E., James C.R., Stewart G.E., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13(24):7413-7420.
37. Steffensen K.D., Waldstrom M., Jeppesen U., Brandslund I., Jakobsen A. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 2008, 18(4):702-710.
38. Walsh C.S., Ogawa S., Karahashi H., et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008, 26(18):2952-2958.
39. Germano G., Frapolli R., Belgiovine C., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23(2):249-262.
40. Ledermann J.A., Raja F.A. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer 2011, 47(Suppl. 3):S104-S115.
41. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997, 15(6):2183-2193.
42. Wagner U., Marth C., Largillier R., et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012, 107(4):588-591.
43. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101(23):1642-1649.
44. Markman M. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol 2007, 106(2):279-281.
45. Cannistra S.A. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?. J Clin Oncol 2010, 28(19):3101-3103.
46. Bast R.C., Thigpen J.T., Arbuck S.G., et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 2007, 107(2):173-176.
47. Gladieff L., Ferrero A., De Rauglaudre G., et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 2012, 23(5):1185-1189.
48. Gadducci A., Tana R., Teti G., Zanca G., Fanucchi A., Genazzani A.R. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008, 18(4):615-620.
49. Pignata S., De Placido S., Biamonte R., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 65.
50. Dunton C.J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 2002, 7(Suppl. 5):11-19.
51. Gordon A.N., Tonda M., Sun S., Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95(1):1-8.
52. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19(14):3312-3322.
53. Tanguay J.S., Ansari J., Buckley L., Fernando I. Epithelial ovarian cancer: role of pegylated liposomal doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer 2009, 19(3):361-366.
54. Bryant C.S., Kumar S., Spannuth W., et al. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Arch Gynecol Obstet 2011, 283(2):361-367.
55. Salazar R., Pardo B., Majem M., et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder. J Clin Oncol 2006, 24:2080. [ASCO Annual Meeting Proceedings - Post-Meeting Edition].
56. Sessa C., De Braud F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005, 23(9):1867-1874.
57. Krasner C.N., McMeekin D.S., Chan S., et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007, 17(19):1618-1624.
58. 23h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009, 20(11):1794-1802.
59. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9(8):2157-2163.
60. Schoffski P., Casali P.G., Taron M., et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006, 24(Suppl. 18):9522.
61. Herrero A.B., Martin-Castellanos C., Marco E., Gago F., Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006, 66(16):8155-8162.
62. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008, 44(4):609-618.
63. Takebayashi Y., Pourquier P., Zimonjic D.B., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001, 7(8):961-966.
64. Damia G., Silvestri S., Carrassa L., et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001, 92(4):583-588.
65. Allavena P., Signorelli M., Chieppa M., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005, 65(7):2964-2971.
66. Germano G., Frapolli R., Simone M., et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010, 70(6):2235-2244.
67. Germano G., Mantovani A., Allavena P. Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Ann Med 2011, 43(8):581-593.
68. Monk B.J., Dalton H., Benjamin I., Tanovic A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012, 18(25):3754-3769.
69. Poveda A., Vergote I., Tjulandin S., et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011, 22(1):39-48.
70. Krasner C.N., Poveda A., Herzog T.J., et al. Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone. Gynecol Oncol 2012, 127(1):161-167.
71. Vermorken J.B., Kelley J., Provencher D., et al. Patient-reported outcomes in patients with relapsed, platinum-sensitive ovarian cancer (ROC): Results from a large randomized phase III trial. Int J Gynecol Cancer 2010, 20(Suppl. 2). [Abstract No. 00458].
72. Vergote I., Bidzinski M., Kelley J., et al. Health-related quality of life (HRQoL)/patient reported outcomes (PRO) of patients with partially platinum sensitive (PPS) recurrent ovarian cancer (ROC) treated in a randomized phase III trial of trabectedin and PLD vs. PLD alone (OVA-301): an exploratory analysis. Eur J Cancer 2011, 47(Suppl. 1):S536.
73. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012, 48(15):2361-2368.
74. Vergote I., Colombo N., Poveda A., et al. Trabectedin+PLD significantly prolongs survival in platinum sensitive+partially platinum sensitive relapsed ovarian cancer patients in comparison to PLD alone. Int J Gynecol Cancer 2011, 21(Suppl. 3). [Abstract: A 373 0000 00474].
75. Poveda A., Tjulandin S., Kong B., et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study. J Clin Oncol 2010, 28(Suppl. 15). [abstr 5012].
76. Hanker L.C., Loibl S., Burchardi N., et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012, 23(10):2605-2612.
77. McMeekin S., Del Campo J.M., Colombo N., et al. Trabectedin (T) in relapsed ovarian cancer (ROC): a pooled analysis of three phase II studies. J Clin Oncol, ASCO Annu Meet Proc Part I 2007, 25(Suppl. 18). [abstract 5579].
78. Vergote I., Meerpohl H.G., Boman K., Nieto A., Tanovic A., Vermorken J.B. Exploratory study of platinum-sensitive (PS) patients who did not achieve a complete response after first-line platinum-based treatment before OVA-301 trial. Int J Gynecol Cancer 2012, 22(Suppl. 3):225.
79. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010, 28(1):154-159.
80. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2007, 25(33):5165-5171.
81. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25(33):5180-5186.
82. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1):76-82.
83. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365(26):2473-2483.
84. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365(26):2484-2496.
85. Cohn D.E., Kim K.H., Resnick K.E., O'Malley D.M., Straughn J.M. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011, 29(10):1247-1251.
86. GOG-213. Carboplatin and paclitaxel with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer (NCT00565851). Available at: ; [accessed 11 20 2012]. http://clinicaltrials.gov/ct2/show/NCT00565851.
87. Aghajanian C., Nycum L.R., Goff B., Nguyen H., Husain A., Blank S.V. Updated overall survival analysis in oceans, a randomized phase 3 trial of gemcitabine (G)+carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritononeal, or fallopian tube cancer. Ann Oncol 2012, 23(Suppl. 9):1057. [Abstract: 967O].
88. Mautner V.F., Nguyen R., Knecht R., Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010, 21(11):2294-2295.
89. Zuniga R.M., Torcuator R., Jain R., et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010, 99(2):237-242.
90. Cacheux W., Boisserie T., Staudacher L., et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 2008, 19(9):1659-1661.
91. Raja F.A., Griffin C.L., Qian W., et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011, 105(7):884-889.
92. Du Bois A., Floquet A., Kim J.W., et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 2013, 31. [abstr LBA5503].
93. Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 2011, 22(Suppl. 8):viii72-viii76.
94. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12(9):852-861.
95. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376(9737):245-251.
96. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366(15):1382-1392.
97. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 2013, 31. [abstr 5505].
98. Kaye S.B., Lubinski J., Matulonis U., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012, 30(4):372-379.
99. Han E.S., Burger R.A., Darcy K.M., et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010, 119(3):484-490.